Hormone Therapy Linked to Fewer Mood Disturbances in Menopause Study

Observational Study Evaluates Mood During Hormone Therapy

A retrospective observational study found that hormone therapy (HT) initiated for physical indications reduced mood disturbances in menopausal women. The research was published in Menopause by lead author Samantha Fairweather and colleagues. Mood disturbances such as depressed mood, irritability, anxiety, and mental exhaustion affect between 45% and 68% of women during the menopause transition.

The United States Food and Drug Administration (FDA) approves HT specifically for hot flashes and genitourinary symptoms rather than psychiatric complaints. Researchers evaluated clinical records from 260 women to examine changes in psychological distress and sleep disruption during routine care. The cohort received systemic estrogen through oral or nonoral routes, paired with a progestogen for women with an intact uterus.

Severe Mood Disturbances Dropped Across the Patient Group

The proportion of patients reporting severe mood symptoms fell from 62.3% to 24.6% following hormone initiation. Patients who entered treatment with the most severe baseline distress experienced the largest overall improvements.

Clinical responses did not differ based on age, menopause stage, psychiatric history, or current antidepressant use. These results suggest that psychological improvements occurred across varied clinical backgrounds when patients began HT for approved indications.

Estrogen Depletion Affects Central Nervous System Function

Estrogen fluctuations during midlife directly alter cerebral blood flow and neurotransmitter activity. Estrogen withdrawal correlates with structural brain changes, whereas estrogen repletion has been linked to improved cortical blood flow, normalized activation patterns, and partial reversal of serotonin imbalances.

Menopausal symptoms frequently persist for 10 or more years, with documented differences across racial and ethnic groups. Black women often experience more severe and longer-lasting hot flashes, while Chinese and Japanese women report lower prevalence and shorter durations. Lower educational attainment and economic strain also correlate with higher overall symptom burdens across populations.

Retrospective Data Limits Direct Causality

A retrospective chart review cannot establish direct causation between hormone therapy and mood improvement. Observational designs lack the randomized placebos necessary to isolate pharmacological effects from natural symptom resolution or supportive clinical care over time.

Because HT remains an off-label consideration for mood regulation, individuals experiencing midlife mood changes should evaluate all options with a qualified healthcare provider. Clinicians can determine whether FDA-approved indications exist and assess potential risks before prescribing systemic hormone therapy.